Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Support.com, Inc. SPRT
$11.80
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
59.69
-
week52low
1.67
-
Revenue
43864000
-
P/E TTM
508
-
Beta
1.09006500
-
EPS
0.00000000
-
Last Dividend
1.00000000
-
Next Earnings Date
13 авг 2021 г. в 04:00
Описание компании
Support.com, Inc. provides customer support services, end user software, and cloud-based software primarily in the United States. The company offers turnkey and outsourced support services for service providers, retailers, original equipment manufacturers (OEMs), warranty providers, Internet of Things solution providers, and other technology companies. Its customer support services programs include pre-purchased concierge advice, device set-up and troubleshooting, inter-operability problem resolution, and virus and malware removal, wireless network set-up, and home security and automation system onboarding and support designed for consumer, and small and medium business markets. The company also provides Support.com Cloud, a software-as-a-service solution for companies to optimize support interactions with their customers using their own or third party support personnel, as well as enables companies to resolve complex technology issues for their customers, provide ease of use for customer self-service, and enhance the customer experience. In addition, it offers end-user software products, including SUPERAntiSpyware for malware protection and removal. The company provides its technology support services through partners. Support.com, Inc. was founded in 1997 and is headquartered in Wilmington, Delaware.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Northland Securities | Market Perform | Outperform | 30 апр 2015 г. |
| Sidoti & Co. | Buy | 14 апр 2014 г. | |
| Northland Securities | Market Perform | Outperform | 08 янв 2014 г. |
| Craig-Hallum | Hold | Buy | 08 янв 2014 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Rosenzweig Lance | D | 0 | 122884 | 14 сент 2021 г. |
| Radoff Bradley Louis | D | 0 | 1301874 | 14 сент 2021 г. |
| ROOK CAROLINE | D | 0 | 32665 | 14 сент 2021 г. |
| Schechter Joshua | D | 0 | 177203 | 14 сент 2021 г. |
| Kowalczyk Christine A. | D | 0 | 18750 | 14 сент 2021 г. |
| Bloom Richard A | D | 0 | 13420 | 14 сент 2021 г. |
| Rosenzweig Lance | D | 0 | 100000 | 14 сент 2021 г. |
| KELLEY BRIAN J | D | 0 | 143870 | 14 сент 2021 г. |
| 210 Capital, LLC | D | 0 | 3909871 | 14 сент 2021 г. |
| ROOK CAROLINE | D | 0 | 32665 | 14 сент 2021 г. |
Новостная лента
Cytokinetics will seek international approval for drug following FDA rejection, says CEO Robert Blum
CNBC Television
01 мар 2023 г. в 15:10
Cytokinetics President and CEO Robert Blum joins 'Power Lunch' to discuss the FDA's rejection of the company's heart failure drug, how FDA approval increases shareholder value and future treatment plans up for FDA approval.